Corporate Banner
Satellite Banner
Biologics & Bioprocessing
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Quattroflow™ to Feature Single-Use Biologic Pumps at INTERPHEX 2013

Published: Monday, January 28, 2013
Last Updated: Sunday, January 27, 2013
Bookmark and Share
Single-use pumps save time and money, and are quick and easy to change.

Quattroflow™ from Almatec® Maschinenbau GmbH, has announced that it will display the latest offerings in its single-use line of pumps for use in biologic-handling applications within pharmaceutical and biotech operations at INTERPHEX 2013 in Booth No. 2463.

The INTERPHEX show, which brings together a wide variety of leaders from the pharmaceutical industry, will be held from April 23-25, 2013, at the Jacob K. Javits Convention Center in New York, NY, USA.

The incorporation of single-use pumps in biologic-handling applications is gaining wider acceptance among pharmaceutical and biotech manufacturers because they can help optimize end-product speed-to-market.

Single-use, or disposable, pumps feature replaceable wetted pump chamber, which is an advantage for manufacturers looking to maximize their production operations.

Quattroflow positive displacement pumps are ideal for single-use systems because they incorporate a four piston-diaphragm technology with no mechanical seals that is driven by an eccentric shaft and motor.

Quattroflow pumps primarily serve the pharmaceutical and biotech industries in applications that require high containment, purity and cleanability, and are best known for transferring shear-sensitive media of aqueous solutions and biological products without damage, ultimately ensuring product safety, efficiency and reliability.

Quattroflow pumps feature wetted pump chambers made of plastic, while the valves are made of EPDM and the diaphragms of EPDM/PP compound.

The Quattroflow product line consists of four sizes - QF150, QF1200, QF4400, QF5050 and QF20K - with capacities of 1 to 20,000 lph (5283 gph).


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,900+ scientific posters on ePosters
  • More than 5,300+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
First New HIV Vaccine Study for Seven Years Begins
South Africa hosts historic clinical trial of experimental HIV vaccine aiming to safely prevent HIV infection.
Vaccination Against UTIs
Researchers have successfully vaccinated mice against E.coli growth in the bladder and kidneys.
First Steps to Neutralising Zika
Researchers have discovered a highly potent antibody that neutralises Zika infection at a cellular level.
Human Astrovirus Structure Could Lead to Therapies, Vaccines
Study shows where neutralizing antibody binds to human astrovirus, a leading cause of viral diarrhoea in children, elderly, and the immune-compromised.
Fighting Off HIV Infection Closer to Reality
Researchers have made significant progress in the development of a potential vaccine to protect against HIV infection.
Powerful New Tools to Combat Zika
Researchers have created a way to replicate the stucture of Zika virus, removing the genes that make the virus infectious.
More Immunotherapy Options Approved for Lung Cancer
The FDA has approved a new immunotherapy drug for certain patients with non-small cell lung cancer.
Dissecting Bacterial Infections at the Single-Cell Level
Researchers have used single-cell analysis technology to provide new insight into the Salmonella infection process.
Injectable Biologic Therapy Reduces Triglycerides
Study finds first-of-its-kind therapy promising for patients with high triglycerides, cholesterol.
DNA-Based Zika Vaccine Showed Protection From Infection, Brain Damage and Death
The study is the first of its kind to analyze a vaccine in an animal model that is susceptible to the disease, providing information regarding the protective impact of the immune response in susceptible individuals.
Skyscraper Banner

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,900+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,300+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!